EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
IBM, Johnson & Johnson Defeat Lawsuit Over 2023 Data Incident
PepsiCo (PEP) Welcomes Johnson & Johnson's Joaquin Duato to Board of Directors - Blockonomi
'AI safety requires immediate action': House Dems demand Johnson cancel recess & take up safeguards - The Economic Times Video | ET Now
Promising Healthcare Stocks To Follow Today - September 18th - Stock Observer
JNJ Announces CHMP's Recommendation For Approval Of TECVAYLI
Johnson & Johnson (JNJ) Advances Sjögren's Therapies With New Biomarker Trial Data - Simply Wall St News
Johnson & Johnson (JNJ) Faces A Fresh Valuation Test On DePuy Sale Talk
Johnson & Johnson $JNJ Shares Sold by Smith Chas P & Associates PA Cpas
Nykredit A S Takes $235.82 Million Position in Johnson & Johnson $JNJ
PepsiCo appoints J&J CEO Joaquin Duato to its board
Apollo Global Management (APO) Eyes DePuy Synthes While Adding $5.5 Billion In Auto Loans
CHMP recommends approval of Johnson & Johnson's TECVAYLI®▼ (teclistamab) in relapsed/refractory multiple myeloma after at least one prior therapy | Valuespectrum.com
PepsiCo names Joaquin Duato to Board of Directors
Johnson & Johnson (NYSE:JNJ) Trading 1.3% Higher - Still a Buy?
Top Pharmaceutical Stocks Worth Watching - September 17th - Markets Daily
Altis Labs' AI software detected treatment benefit earlier in oncology trial
Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff - Stock Observer
The Manufacturers Life Insurance Company Has $951.49 Million Stock Position in Johnson & Johnson $JNJ
Van Hulzen Asset Management LLC Has $30.19 Million Stake in Johnson & Johnson $JNJ
Core Capital Management & Research inc. Buys Shares of 4,002 Johnson & Johnson $JNJ
Archford Capital Strategies LLC Has $10.32 Million Stock Holdings in Johnson & Johnson $JNJ
Color patterns as a model for connecting developmental mechanisms to phenotypic evolution
J&J Slips as Caplyta Clears a Quality-of-Life Test
Should You Judge JNJ Stock Without STELARA?
Monthly Paydays vs. Compound Growth: Why JNJ Beats O for Long-Term Retirees
Abiomed Gets Benefit Plan Exemption for Johnson & Johnson Deal
Best Healthcare Stocks To Follow Today - September 16th - Stock Observer
Will Your Organization Stand By Its Values-Even When It's Hard?
Johnson & Johnson $JNJ Shares Sold by HighTower Advisors LLC
Waverly Advisors LLC Buys 42,556 Shares of Johnson & Johnson $JNJ
HORAN Wealth LLC Decreases Stock Position in Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Shares Bought by Arizona State Retirement System
Anchor Capital Advisors LLC Sells 5,801 Shares of Johnson & Johnson $JNJ
Amundi Decreases Stock Position in Johnson & Johnson $JNJ
Allworth Financial LP Sells 49,306 Shares of Johnson & Johnson $JNJ
Epidemiology, mechanisms and clinical implications of heat-related kidney disease
Johnson & Johnson Partner Contineum Slides as Depression Drug Fails
Apollo and J&J Face a High-Stakes Orthopedics Deal
From Coca-Cola to OpenAI, Brands Are Betting Bigger on OOH
Companies Push for Litigation Funding Disclosure: Delaware Brief
3 Dividend Stocks Baby Boomers Should Own for the Rest of Their Lives
Johnson & Johnson $JNJ Shares Purchased by Groupe la Francaise
Saudi Central Bank Increases Stock Position in Johnson & Johnson $JNJ
VIRGINIA RETIREMENT SYSTEMS ET Al Makes New $207.87 Million Investment in Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Shares Acquired by Ameritas Advisory Services LLC
The Global Expansion Narrative of Chinese Innovative Drugs: A Game-Changing Development Set to Unfold in Two Weeks
JNJ Q3 2026 Earnings Report on 10/13/2026
Rep. Thomas H. Kean, Jr. Sells Off Johnson & Johnson (NYSE:JNJ) Shares
Contineum's Phase 2 MOONLIGHT-1 Trial Misses Primary Endpoint In MDD; Stock Down
RYBREVANT FASPRO plus LAZCLUZE® with prophylactic strategies shows low rates of treatment-related events at WCLC 2026 | INN
Contineum Therapeutics Shares Fall After Drug Trial Missed Primary Endpoint | Morningstar
Contineum Therapeutics Reports Phase 2 Results for JNJ-5120/PIPE-307 for the Treatment of Major Depressive Disorder | Morningstar
Apollo rumoured to be eyeing $20bn takeover of J&J's orthopaedics business
Johnson & Johnson Shares Rise on Reported Apollo Talks for Orthopedics Unit
Top Pharmaceutical Stocks To Research - September 14th - Daily Political
Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition - Daily Political
J&J's RYBREVANT Plus Chemotherapy Sets New Benchmark In EGFR Exon 20 Insertion NSCLC Survival
Zacks Investment Ideas feature highlights: Johnson & Johnson, Coca-Cola and Exxon Mobil
Compass Financial Management LLC Invests $1.42 Million in Johnson & Johnson $JNJ
Bank of America Corp DE Sells 2,078,556 Shares of Johnson & Johnson $JNJ
Azimuth Capital Investment Management LLC Sells 3,870 Shares of Johnson & Johnson $JNJ
Pharmaceutical Stocks To Keep An Eye On - September 13th - Daily Political
Johnson & Johnson $JNJ Shares Bought by Concurrent Investment Advisors LLC
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
The Closest Thing to Set-It-and-Forget-It Income: 5 Dividend Kings for Retirees Who Want Peace of Mind
Pharmaceutical Stocks To Follow Today - September 12th - Stock Observer
PYA Waltman Capital LLC Has $11.44 Million Position in Johnson & Johnson $JNJ - Markets Daily
Burford Brothers Inc. Decreases Stake in Johnson & Johnson $JNJ
Johnson & Johnson $JNJ Stock Holdings Lifted by PYA Waltman Capital LLC - Stock Observer
Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage - Stock Observer
J&J orthopedics unit draws Apollo interest in potential $20 billion deal: Report - The Economic Times
Apollo Global in talks to buy J&J's orthopedics unit, Bloomberg reports
Apollo Global Is Said in Talks to Acquire J&J's Orthopedics Unit
Is AbbVie Stock Actually Overpriced?
Meet Ottava, J&J's surgical robot leading the healthcare giant into a lucrative new market
3 Top Dividend Aristocrats To Own Near All-Time Highs
Johnson & Johnson (NYSE:JNJ) Receives Consensus Rating of "Moderate Buy" from Brokerages - Zolmax
J&J's new reusable contact lens secures CE Mark
Rinkey Investments Reduces Holdings in Johnson & Johnson $JNJ
Proficio Capital Partners LLC Boosts Position in Johnson & Johnson $JNJ
Proficio Capital Partners LLC Increases Stock Position in Johnson & Johnson $JNJ - Markets Daily
Lone Peak Global Investors LLC Decreases Holdings in Johnson & Johnson $JNJ
New Technologies and Achievements Make Concentrated Debuts, Highlighting CIFTIS as a Platform for Innovation | AsiaNet
RBC Capital Sticks to Its Buy Rating for Johnson & Johnson (JNJ)
Johnson & Johnson $JNJ Shares Sold by XML Financial LLC - Daily Political
Rinkey Investments Cuts Stake in Johnson & Johnson $JNJ - Daily Political
Johnson & Johnson Receives CE Marking For ACUVUE OASYS MAX 2-Week Contact Lenses
J&J names two-decade veteran as chief IP counsel | Careers | Life Sciences Intellectual Property Review
J&J unit win shuts door on Sandoz generic launch | Pharma | Life Sciences Intellectual Property Review
Johnson & Johnson $JNJ Shares Sold by Meiji Yasuda Life Insurance Co - Zolmax
Northwestern Mutual Wealth Management Co. Has $93.80 Million Stock Holdings in Johnson & Johnson $JNJ - Zolmax
Nichols & Pratt Advisers LLP MA Lowers Holdings in Johnson & Johnson $JNJ
Montanova Capital LLC Has $1.96 Million Position in Johnson & Johnson $JNJ
Sigma Planning Corp Boosts Stock Holdings in Johnson & Johnson $JNJ
Latest news
Show more
Global Market Review: Gold Volatility and Tech Stock Surge Amidst Economic Uncertainty
September CPI Data: Inflation Hurdles, Tariff Impacts, and Fed Rate Cut Expectations
Navigating the AI Boom: Strategies for Investors Amid Nvidia's Valuation Surge
